Loading asset research
Q3 2026 earnings · Oct 27
Kiniksa Pharmaceuticals International plc Class A Ordinary Shares
KNSANasdaq · USD · StocksQuote as of · Exchange session not verified$76.24
-0.31%
Today
KNSA
Loading 1D prices…
Market cap
$6B
Volume
576.5K
52w high
$82.9452w low
$35.20Company profile
Kiniksa Pharmaceuticals International plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
London, United States
Employees
366
Fiscal year end
1231
CIK
1730430
Session & valuation
Open$77.70
Previous close$76.48
Day high$78.59
Day low$76.14
30-day avg. volume492.1K
Outstanding shares—
Diluted EPS$0.75
Latest annual period
P/E (trailing)77.04
P/E (forward)47.15
Price / book9.09
Beta0.09
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| DNTHDianthus Therapeutics Inc. Common Stock | $5.9B | $2M | -7973.33% | -$4.20 | +2.83% | Buy |
| LQDALiquidia Corporation Common Stock | $6B | $158.3M | -43.53% | -$0.80 | -1.68% | Buy |
| AMRXAmneal Pharmaceuticals Inc. Class A Common Stock | $5.9B | $3B | +2.39% | $0.22 | +0.86% | Buy |
| COGTCogent Biosciences Inc. Common Stock | $5.8B | $0.00 | — | -$2.16 | -1.97% | Buy |
| ORKAOruka Therapeutics Inc. Common Stock | $6.1B | $0.00 | — | -$1.85 | +0.78% | Buy |